Immune checkpoint inhibitors as a threat to reproductive function: A systematic review

Crit Rev Oncol Hematol. 2023 Aug:188:104064. doi: 10.1016/j.critrevonc.2023.104064. Epub 2023 Jun 27.

Abstract

In recent years, the indications for immunotherapy in cancer treatment have been expanding. The increased risk of cancer in young people, coupled with the fact that many women or men choose to delay childbearing, has made an increasing number of patients of childbearing age eligible for immunotherapy. Furthermore, with the improvements of various treatments, more young people and children are able to survive cancer. As a result, long-term sequelae of cancer treatments, such as reproductive dysfunction, are increasingly important for survivors. While many anti-cancer drugs are known to cause reproduction dysfunction, the effects of immune checkpoint inhibitors (ICIs) on reproduction function remain largely unknown. Through a retrospective analysis of previous reports and literature, this article aims to elucidate the causes of reproductive dysfunction induced by ICIs and focus on their specific mechanisms, in order to providing some guidance to clinicians and patients.

Keywords: Hypogonadism; Hypophysitis; Immune checkpoint inhibitors; Immune-related adverse events; Infertility; Reproductive dysfunction.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Adolescent
  • Antineoplastic Agents* / therapeutic use
  • Child
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / adverse effects
  • Male
  • Neoplasms*
  • Retrospective Studies

Substances

  • Immune Checkpoint Inhibitors
  • Antineoplastic Agents